Dupixent Injury Lawyers in Philadelphia, PA
Research findings have linked an injectable medication called Dupixent, widely used to treat eczema, asthma, and other inflammatory conditions, to a rare but aggressive form of skin cancer. For the patients who developed life-threatening harm connected to this medication and their families, legal action offers an opportunity to hold drug manufacturers accountable, recover compensation for medical costs and other financial losses, and seek justice. The Dupixent lawsuit attorneys at Anapol Weiss are currently investigating cases. We’re ready to use our extensive experience as national leaders in defective drug cases to pursue maximum compensation for our clients.
Attorney Tracy A. Finken Magnotta, who is leading the Dupixent lawsuit practice area at Anapol Weiss, has recovered over $750 million for her clients in a wide range of product liability and pharmaceutical liability matters. Tracy is a leader in pharmaceutical liability cases, having been appointed to leadership roles in a number of mass tort and multi-district litigations, including Depo-Provera litigation, Tepezza litigation, Zantac litigation, and proton pump inhibitor litigation.
With new Dupixent lawsuits continuing to be filed and more research into the link between the medication and cancer emerging in recent months, these cases are time-sensitive and evolving quickly. Our team is ahead of the latest developments, with cutting-edge resources for investigating potential claims and access to experts whose testimony can strengthen your case.
Don’t wait to speak with our Dupixent injury lawyers in Philadelphia, PA, about your rights, your legal options, and your eligibility for a claim. We fight for more than just a payout, securing the resources you need to afford the highest quality of medical care, support your family, and meaningfully impact your quality of life. We begin every case with a free, confidential consultation. Contact us today for the guidance and legal support you need.
Who Can File a Dupixent Cancer Lawsuit?
At this time, our Dupixent lawsuit attorneys are investigating claims on behalf of individuals who:
- Took the injectable biologic medication Dupixent (also known by its generic name, dupilumab), and
- Have been diagnosed with cutaneous T‑cell lymphoma (CTCL) skin cancer, including subtypes of this rare but aggressive condition such as mycosis fungoides and Sézary syndrome
Due to the aggressive nature of certain subtypes of CTCL, some instances of cancer potentially linked to Dupixent exposure have been terminal. Our team also provides compassionate legal representation for wrongful death actions on behalf of surviving family members of cancer patients.
During a free, no-obligation consultation, we will review the unique facts of your situation and advise you on whether you may have grounds to pursue compensation.
You don’t have to face a cancer battle or a legal battle alone. We’re here to guide your next steps with care, compassion, and a commitment to justice.
How a Dupixent Lawsuit Can Help Cancer Patients and Their Families
A cancer diagnosis can change your world. Suddenly, you’re worrying about staging tests, oncologist appointments, difficult treatments, and spiraling medical costs. In many cases, a cancer patient becomes too sick to work. This sudden loss of income can add to your hardships and make it impossible to support your family.
Nothing about this situation is fair, especially when you have reason to believe that your cancer could have been caused by a medication you were taking. When a drug manufacturer’s failure to adequately warn patients of a medication’s risks has contributed to your illness, the pharmaceutical company could potentially be held liable for your losses.
For cancer patients and their families, filing a Dupixent lawsuit can make a meaningful difference by:
- Providing financial resources that allow you access to the most promising medical interventions available
- Ensuring economic support for your family while you’re too sick to work
- Addressing the very real physical pain and emotional distress you’re suffering
- Offering a means of affording ongoing care and monitoring, even after remission
- Addressing grieving family members’ financial hardships and their loss of emotional support and connection following a death
- Holding the pharmaceutical companies that put profits ahead of people legally and financially responsible for the devastating results of their actions
Taking legal action can’t erase the harm you and your family have suffered, but it can provide critical support for the difficulties you’re facing when diagnosed with a form of cancer like CTCL.
Dupixent and Cancer
As preliminary litigation against drug manufacturers moves forward, our Dupixent lawsuit attorneys are at the forefront of these complex cases. We’re ready to provide the support our clients need to attain accountability, financial compensation, and justice.
What Patients Need to Know About Dupixent
Dupixent, known generically as dupilumab, was first approved by the U.S. Food & Drug Administration in 2017 to treat eczema. Since then, the uses (approved, off-label, and in clinical trial) of the injectable drug have grown to encompass:
- Moderate-to-severe atopic dermatitis
- Asthma (most commonly eosinophilic or oral-steroid dependent forms)
- Chronic obstructive pulmonary disease (COPD), which causes breathing difficulties
- Bullous pemphigoid (BP), an autoimmune skin disorder
- Chronic spontaneous urticaria (CSU), a skin condition characterized by hives and swelling caused by overactive immune cells
- Prurigo nodularis, a skin condition in which small, itchy, raised nodules or lesions develop on the skin
- Chronic rhinosinusitis with nasal polyps, in which inflammation and accompanying non-cancerous growths block the nasal passages and cause congestion
- Eosinophilic esophagitis, or inflammation of the esophagus characterized by an increase in white blood cells in the lining of the esophagus
Developed jointly by pharmaceutical companies Sanofi and Regeneron, Dupixent is part of a class of medications known as biologics, which means they are derived from living organisms. Just because a medicine is classified as a biologic doesn’t prevent the drug from posing significant risks.
Inflammation plays an important part in how the body’s immune system fights injuries and infections. However, in the case of eczema, asthma, and other inflammatory conditions, inflammation may be triggered when it’s not necessary or helpful. Injections of Dupixent and generic dupilumab work by obstructing two pathways, interleukin-4 (IL-4) and interleukin-13 (IL-13), through which the body’s immune system signals and produces inflammation.
Altering these immune system pathways can help reduce itching, breathing difficulties, and other symptoms of inflammation, which is why the treatment has become so widely used in addressing inflammatory medical conditions. But researchers now believe that this change may be associated with the development or unmasking of previously undiagnosed CTCL.
Multiple research studies have demonstrated an elevated risk of CTCL skin cancer among patients who took Dupixent. Yet the manufacturers still do not warn of this risk.
Types of Cancer Linked to Dupixent Exposure
Specifically, researchers have uncovered a link between the use of Dupixent and the risk of a type of non-Hodgkin lymphoma known as cutaneous T-cell lymphoma (CTCL).
- The term “cutaneous” refers to the fact that CTCL primarily affects the skin.
- “T-cell” refers to the T-lymphocytes, the type of white blood cells, found in the body’s immune system, in which this cancer develops.
- Lymphoma is a type of blood cancer that starts in the lymphatic system.
Cutaneous T-cell lymphoma isn’t one type of cancer but rather a group of rare cancers, as the American Academy of Dermatology Association noted. There are numerous subtypes of CTCL, including:
- Mycosis fungoides
- Sézary syndrome
- Primary cutaneous anaplastic large cell lymphoma
- Subcutaneous panniculitis-like T-cell lymphoma
- Adult T-cell leukemia/lymphoma
- Primary cutaneous gamma-delta T-cell lymphoma
- Extranodal NK/T-cell lymphoma
- Hydroa vacciniforme-like lymphoproliferative disorder
- Lymphomatoid papulosis
The most common form of CTCL is mycosis fungoides, which accounts for more than half of all cutaneous T-cell lymphoma diagnoses. Because mycosis fungoides is a slow-growing cancer, it’s also among the more treatable forms of CTCL.
Although rarer, Sézary syndrome is the other main type of CTCL. This cancer is rarer but also more aggressive. It grows faster, affects the blood, and can potentially spread throughout the body.
Other rare T-cell lymphomas may have varying relationships with the skin, and because of that, these subtypes are not always included under cutaneous T-cell lymphoma in every classification.
Symptoms of CTCL skin cancer include:
- Red, dry, scaly patches on the skin
- Skin rashes
- Skin bumps, lumps, and tumors
- Thickened skin
- Discoloration of the skin
- Itching
- Swollen lymph nodes
- Fever
- Chills
- Night sweats
- Hair loss
- Unexplained weight loss
- Pain or tenderness
Many of these symptoms that could indicate CTCL at the early stages are skin-related. Given that many patients are taking Dupixent for eczema or other conditions that involve inflammation of the skin, these symptoms are often overlooked, particularly since the drug manufacturers failed to warn patients of the increased risk of skin cancer.
For many patients, a delay in recognizing these symptoms can contribute to missed opportunities for early detection and, in turn, a worsened prognosis.
Research Findings Connecting Dupixent and CTCL
Throughout 2024 and 2025, a number of research studies published in peer-reviewed journals reported findings that linked dupilumab with CTCL skin cancer. Even after adjusting for various risk factors, multiple studies found significant increases in CTCL skin cancer risk among patients taking dupilumab. Depending on the specific factors the researchers considered, increased risks as high as 2, 3, or even 4.5 times that of the control group have been reported.
Even though the absolute risk of developing these rare cancers remains low, these observational studies have shown elevated relative risks that are as concerning as they are meaningful.
Other reports have demonstrated worsening CTCL in connection with Dupixent treatment. A patient may be prescribed Dupixent for what is assumed to be atopic dermatitis, only for the medication to accelerate what is, in fact, a form of skin cancer. Since the drug manufacturers failed to warn of this risk, by the time many patients learned the truth, the medication they were taking may have already contributed to further progression of their illness.
Filing a Dupixent Cancer Lawsuit
Because much of the research establishing a link between the inflammation drug Dupixent and CTCL skin cancer has only emerged in recent years, lawsuits against the medication’s manufacturers are still in the early stages. However, dozens of instances of cutaneous T‑cell lymphoma have been reported among Dupixent users, and some lawsuits are already being filed in courts throughout the country.
At Anapol Weiss, we’re taking a strong stance against pharmaceutical manufacturers. Through the legal actions we intend to file on behalf of our clients, we plan to hold companies accountable for:
- Minimizing signs of an increased risk of developing CTCL skin cancer
- Ignoring indications of potential worsening of these skin cancers during Dupixent treatment
- Failing to warn patients and providers of this increased risk, which interfered with the ability to make informed medical decisions
- Contributing to the delayed diagnosis of CTCL and potentially to a worse prognosis
Through the legal process, we can recover financial compensation that addresses all of your legally recognizable losses. In cases that involve aggressive cancers, both your economic and non-economic losses can be significant. Whether we’re negotiating a settlement out of court or fighting tirelessly for you at trial, we focus on obtaining an outcome that fully and fairly speaks to the harm our clients have suffered.
How the Dupixent Injury Lawyers in Philadelphia, PA, at Anapol Weiss Can Help Hold Drugmakers Accountable
To hold a pharmaceutical manufacturer legally and financially accountable for harm caused by their product, you need to present strong evidence in your favor. At Anapol Weiss, our Dupixent lawsuit attorneys are prepared to handle every demand involved in your claim. We build cases and present compelling claims in court backed by evidence such as:
- Records from your dermatologist or other medical providers, including photographs, lesion maps, and appointment summaries
- Pathology reports, including biopsy findings, T-cell receptor studies, and results of immunohistochemistry laboratory tests
- Your diagnosis and all provider notes leading up to it, which can establish when CTCL skin cancer was suspected and confirmed
- Medication history records that show the timeline of when you started and stopped taking Dupixent, dosage amounts, and any response or side effects reported
- Expert testimony that speaks to the link between Dupixent and CTCL skin cancer
- Documentation of your losses, which can range from medical expenses and wage loss during illness to ongoing care needs, pain and suffering compensation, and even wrongful death compensation for surviving family members
We know that fighting a cancer battle or facing grief is demanding enough on its own without having to worry about the legal process. As experienced defective drug attorneys, we’re here to manage every aspect of your case for you.
Why Choose Anapol Weiss as Your Dupixent Lawsuit Attorneys?
For help pursuing a claim against the manufacturers of Dupixent, you need the trusted legal guidance of a longstanding law firm that has a history of getting results, a reputation for holding pharmaceutical companies accountable, and experience leading complex defective drug cases.
A Proven Record of High-Value Results
The experienced legal team at Anapol Weiss has successfully litigated thousands of cases in state and federal courts to secure our clients billions of dollars. We have a history of achieving high-value verdicts, settlements, and judgments through our unwavering commitment to clients, our meticulous case preparation, and our compelling presentations of our clients’ claims at trial.
Our History of Taking on Major Pharmaceutical Companies and Other Corporations
Our law firm never backs down from taking legal action against influential corporations, including multinational companies like Sanofi and Regeneron. These massive corporations have the resources and legal counsel that individuals don’t, but our dedicated advocacy on behalf of plaintiffs nationwide can level the playing field and ensure that you have a real opportunity to pursue accountability.
Legal Leaders in Mass Tort, Class Action, and Multidistrict Litigation
When widely used medications are found to pose increased risks of serious harm, numerous patients can be injured through the same mechanisms. Although there is no mass tort Dupixent skin cancer lawsuit at this time, our attorneys are currently investigating individual injury claims and are prepared for the possibility of once again taking on leadership roles in multidistrict litigations, as we have done repeatedly in the past.
Contact the Dupixent Lawsuit Attorneys at Anapol Weiss Today for a Free Case Review
Nothing should stand in the way of getting the justice you deserve and the compensation you and your family need. Our pharmaceutical injury attorneys do more than handle cases. We give victims a voice in a legal system where drugmakers and other major corporations are too often able to silence those harmed by their failures. We believe in standing up for what’s right, and that means protecting patients, consumers, and families.
With legal representation available at no upfront cost and the comprehensive support your case demands at every stage of the claims process, you have nothing to lose and so much to gain through a Dupixent lawsuit. Take the first step today with your free consultation.
For help from our Dupixent injury lawyers in Philadelphia, PA, contact Anapol Weiss online or call 215-608-9645 today.